Health Law Alliance, specializing in PBM audit defense, highlights the potential benefits of discrepant PBM audits as early warnings for broader government investigations. The article underscores the importance of strategic planning, including OIG self-disclosures, to reduce liability for providers facing PBM audits and government inquiries.

PBM audits may reveal a window of opportunity for providers to significantly reduce potential liability to government payors. Health Law Alliance specializes in the defense of PBM audits, and routinely assists clients to manage PBM audit risk through strategic planning, including consideration of OIG-self disclosures.

Window Opportunity

If asked, every single provider would say that nothing good can come from a PBM audit. And they would be exactly right. Almost.

The One (and Only) Benefit of a Discrepant PBM Audit

There is one scenario (only one) in which a PBM audit may be helpful to provide notice of potential risk, and permit a small window of time in which to react. Specifically, PBM audits can be viewed as the "canary in a coal mine" because a discrepant PBM audit may signal that a broader government investigation will follow.

So you ask, how can a PBM audit possibly be a good thing? The answer is simple: if the PBM audit reveals concerns regarding the audit sample that apply to a broader universe of potentially problematic claims.

The following example helps illustrate the point: CVS Caremark conducts an audit that targets a high-reimbursing item paid by Medicaid and commercial plans. During the audit, physicians deny prescribing the item, and patients claim they never received and did not use the item. The pharmacy obtains a few attestations, but CVS reverses the claims and recoups from reimbursements due the pharmacy.

The Severe Downside to a Discrepant PBM Audit

Now, at this point, many providers would conclude that CVS has been satisfied, the audit is finished, and the matter closed. In many scenarios, they could not be more wrong.

PBMs and other MCOs are obligated to refer cases to government regulators that involve potential or suspected fraud, waste or abuse. In the example above, CVS determined that its investigative findings required a referral to the State's MFCU, with whom CVS maintains close relations because CVS hires many former government investigators after they leave public service. Accordingly, CVS's referral is readily accepted, and the State commences an investigation.

Ultimately, the MFCU concludes that the pharmacy was billing the high-reimbursing item improperly because it was offering kickbacks to physicians for the referrals in the form of prior-authorization support. The pharmacist is threatened with criminal prosecution or a lawsuit under the False Claims Act involving treble damages and crushing mandatory penalties. This exact fact-pattern plays out everyday across the country.

The Window of Opportunity Presented by a Discrepant PBM Audit

In our example, the window of opportunity presented by the audit has closed, and the provider's options are far more limited. Had the pharmacist made a self-disclosure, it is possible that this scenario would have been avoided. Specifically, OIG operates a voluntary forgiveness program, referred to as the Self-Disclosure Protocol (SDP), that providers can use to significantly reduce their risk at any point prior to the commencement of a government investigation. Accordingly, if a provider becomes aware of potentially invalid claims, whether through an audit or not, a voluntary OIG disclosure can be made to prevent a larger problem.

The OIG's Self-Disclosure Protocol applies to a wide range of conduct, including potential fraud and violations of federal criminal, civil, or administrative laws, including violations of the Anti-Kickback Statute and false billing. In conclusion, after the PBM audit in our example, the provider had an opportunity to self-report using OIG's Self-Disclosure Protocol across all potentially problematic claims, not just the ones that were subject to audit.

Whether an OIG Self-Disclosure is Right for You

The preparation and filing of an OIG self-disclosure can be complicated and time-consuming, so consideration should be given at the outset of any audit whether to begin preparations for a disclosure. Finally, an OIG self-disclosure ensures that the government claims are paid, which often does not happen when a PBM imposes recoupment.

HLA routinely assists providers to evaluate the best possible strategy for responding to a PBM audit or government inquiry. At times, that strategy may involve an OIG self-disclosure. Click HERE to schedule a free consultation today and speak to one of our experienced healthcare defense attorneys regarding whether an OIG disclosure is right for you.

Frequently Asked Questions

Pharmacy Benefit Managers (PBMs) Face Possible FTC Lawsuit

The Federal Trade Commission (FTC) plans to sue the top Pharmacy Benefit Managers (PBMs) for anti-competitive practices, including influencing drug prices and favoring their own networks, which disadvantage independent pharmacies and raise prescription drug costs.


Victories Against Optum Rx: Protecting Pharmacy Clients Nationwide

Health Law Alliance has successfully challenged Optum Rx's termination decisions for numerous pharmacies, ensuring they can continue to operate and serve their communities. These victories highlight the firm's expertise in healthcare law and its dedication to protecting pharmacy clients from unjust PBM actions.


FTC Issues Interim Report Condemning Anticompetitive PBM Practices

The top Pharmacy Benefit Managers (PBMs) are condemned by the FTC for manipulating the healthcare system to generate significant profits, thereby inflating drug costs and overcharging patients, particularly for critical medications like cancer drugs.


Seized Ozempic Shipments Highlight Rising Demand and Safety Concerns

Ozempic, a well-known medication for type 2 diabetes, has gained popularity for its off-label use in weight loss, leading to increased scrutiny by authorities. Recently, U.S. Customs and Border Protection (CBP) officers in Cincinnati seized several shipments of the drug, underscoring the growing demand and associated risks.